ICU Medical, Inc. (NASDAQ:ICUI) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have been assigned an average rating of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $176.50.

Several research analysts have commented on ICUI shares. Piper Sandler raised their target price on ICU Medical from $145.00 to $153.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 10th. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Friday, September 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ICU Medical in a research note on Wednesday, October 8th. Raymond James Financial lowered their target price on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a research note on Friday, August 8th. Finally, KeyCorp decreased their price target on shares of ICU Medical from $191.00 to $173.00 and set an “overweight” rating on the stock in a report on Tuesday, October 21st.

Insider Activity

In other ICU Medical news, Director David C. Greenberg purchased 1,200 shares of the company’s stock in a transaction dated Wednesday, August 27th. The stock was purchased at an average price of $126.42 per share, for a total transaction of $151,704.00. Following the transaction, the director owned 7,960 shares in the company, valued at $1,006,303.20. The trade was a 17.75% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Vivek Jain acquired 21,929 shares of the business’s stock in a transaction dated Thursday, August 14th. The shares were acquired at an average cost of $112.84 per share, with a total value of $2,474,468.36. Following the acquisition, the chief executive officer directly owned 130,149 shares of the company’s stock, valued at $14,686,013.16. This represents a 20.26% increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 1.50% of the company’s stock.

Institutional Trading of ICU Medical

A number of hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC boosted its holdings in shares of ICU Medical by 27.2% during the first quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 153 shares during the period. Vontobel Holding Ltd. purchased a new position in ICU Medical during the 1st quarter valued at about $235,000. EP Wealth Advisors LLC bought a new position in ICU Medical during the 1st quarter valued at approximately $479,000. Vident Advisory LLC purchased a new stake in ICU Medical in the 1st quarter worth approximately $270,000. Finally, Envestnet Asset Management Inc. grew its position in shares of ICU Medical by 8.2% in the 1st quarter. Envestnet Asset Management Inc. now owns 20,269 shares of the medical instruments supplier’s stock worth $2,815,000 after buying an additional 1,534 shares during the last quarter. 96.10% of the stock is owned by institutional investors.

ICU Medical Stock Performance

NASDAQ ICUI opened at $125.66 on Wednesday. The company’s 50 day moving average is $123.81 and its 200-day moving average is $128.19. The firm has a market cap of $3.10 billion, a P/E ratio of -82.67 and a beta of 0.83. ICU Medical has a 12-month low of $107.00 and a 12-month high of $196.26. The company has a quick ratio of 1.17, a current ratio of 2.44 and a debt-to-equity ratio of 0.63.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share for the quarter, beating analysts’ consensus estimates of $1.44 by $0.66. The business had revenue of $543.57 million during the quarter, compared to analyst estimates of $543.33 million. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. ICU Medical’s revenue was down 8.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.56 EPS. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. Sell-side analysts predict that ICU Medical will post 4.11 earnings per share for the current year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.